Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (89 ops.)
Latest filing published 25 Aug 2026 for Ardelyx, INC., €50k.
Filing timeline
BuySaleMichael Raab
Insider track record
Disclosed buys
1
Disclosed sells
89
T+90 hit rate
100%
T+90 mean return
+139.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Michael Raab: trading record in brief
Michael Raab (chief executive) discloses dealings in 2 companies, chiefly Ardelyx, Inc. and Amicus Therapeutics, Inc. In total, 141 filings cover trades dated from 19 January 2017 to 21 August 2026.
On the open market, the record shows 1 purchase worth €1,849 and 89 sales worth €8.2M. Taken together, the sales exceed the purchases by €8.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 20 share grants and 29 option exercises. So far in 2026, the count stands at no purchases and 19 sales.
The latest filing, published on 25 August 2026, reports an open-market sale of €50k in Ardelyx, Inc. The latest purchase dates back some time: it was published 1,513 days ago, on 1 September 2022. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Michael Raab
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations82 total
15,009 shares@ US$3.8569Common StockSEC:0001321402-26-000019:0
15,976 shares@ US$3.8569Common StockSEC:0001321402-26-000019:1
8,411 shares@ US$3.8569Common StockSEC:0001321402-26-000019:2
19,178 shares@ US$3.8569Common StockSEC:0001321402-26-000019:3
41,668 shares@ US$5.0620.017% mcap4.5% of flowCommon StockSEC:0001321402-26-000016:1
20,834 shares@ US$0.990.0016% mcap0.4% of flowCommon StockSEC:0001321402-26-000016:0
20,833 sharesCommon StockSEC:0001321402-26-000014:0
41,666 sharesCommon StockSEC:0001321402-26-000014:1
14,933 shares@ US$6.26750.0090% mcap2.5% of flowCommon StockSEC:0001321402-26-000012:0
17,926 shares@ US$6.26750.011% mcap3.1% of flowCommon StockSEC:0001321402-26-000012:2
14,028 shares@ US$6.26750.0084% mcap2.4% of flowCommon StockSEC:0001321402-26-000012:3
7,861 shares@ US$6.26750.0047% mcap1.3% of flowCommon StockSEC:0001321402-26-000012:1
41,666 shares@ US$6.27880.025% mcap7.1% of flowCommon StockSEC:0001321402-26-000009:1
20,833 shares@ US$0.990.0020% mcap0.6% of flowCommon StockSEC:0001321402-26-000009:0
115,857 shares@ US$14.500.036% mcap84.1% of flowCommon StockSEC:0001193125-26-182264:0
41,668 shares@ US$6.28670.019% mcap6.5% of flowCommon StockSEC:0001321402-26-000008:1
20,834 shares@ US$0.990.0015% mcap0.5% of flowCommon StockSEC:0001321402-26-000008:0
20,833 shares@ US$0.990.5% of flowCommon StockSEC:0001321402-26-000006:0
20,833 shares@ US$0.990.5% of flowCommon StockSEC:0001610717-26-000067:0
40,401 shares@ US$5.8655.4% of flowCommon StockSEC:0001610717-26-000058:0
446,220 shares0Common StockSEC:0001610717-26-000022:0
46,887 shares@ US$5.53697.1% of flowCommon StockSEC:0001610717-25-000396:0
45,687 shares@ US$5.93176.6% of flowCommon StockSEC:0001628280-25-041135:0
20,414 shares0Common StockSEC:0000950170-25-083223:0
46,817 shares@ US$4.08145.3% of flowCommon StockSEC:0001628280-25-027429:0
25 of 82 declarations
